Analysts See $-0.10 EPS for CorMedix, Inc. (CRMD); 2 Analysts Covering Alliqua BioMedical, Inc. (ALQA)

May 8, 2018 - By Michael Collier

Alliqua BioMedical, Inc. (NASDAQ:ALQA) Logo

Analysts expect CorMedix, Inc. (NYSEAMERICAN:CRMD) to report $-0.10 EPS on May, 9.They anticipate $0.09 EPS change or 47.37% from last quarter’s $-0.19 EPS. After having $-0.15 EPS previously, CorMedix, Inc.’s analysts see -33.33% EPS growth. The stock decreased 0.85% or $0.002 during the last trading session, reaching $0.233. About 244,268 shares traded. CorMedix, Inc. (NYSEAMERICAN:CRMD) has declined 88.81% since May 8, 2017 and is downtrending. It has underperformed by 100.36% the S&P500.

Among 3 analysts covering Alliqua Biomedical (NASDAQ:ALQA), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Alliqua Biomedical had 12 analyst reports since August 19, 2015 according to SRatingsIntel. The stock of Alliqua BioMedical, Inc. (NASDAQ:ALQA) earned “Hold” rating by Zacks on Wednesday, August 19. The stock of Alliqua BioMedical, Inc. (NASDAQ:ALQA) earned “Outperform” rating by RBC Capital Markets on Wednesday, February 24. The stock of Alliqua BioMedical, Inc. (NASDAQ:ALQA) earned “Buy” rating by H.C. Wainwright on Wednesday, August 10. The stock of Alliqua BioMedical, Inc. (NASDAQ:ALQA) has “Buy” rating given on Monday, November 2 by H.C. Wainwright. The stock has “Buy” rating by H.C. Wainwright on Friday, April 7. H.C. Wainwright downgraded the shares of ALQA in report on Monday, January 8 to “Neutral” rating. Chardan Capital Markets maintained Alliqua BioMedical, Inc. (NASDAQ:ALQA) rating on Wednesday, February 24. Chardan Capital Markets has “Buy” rating and $2.25 target. As per Friday, November 6, the company rating was maintained by Chardan Capital Markets. RBC Capital Markets maintained the shares of ALQA in report on Friday, November 6 with “Outperform” rating. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, January 3. See Alliqua BioMedical, Inc. (NASDAQ:ALQA) latest ratings:

08/01/2018 Broker: H.C. Wainwright Old Rating: Buy New Rating: Neutral Old Target: $1.5 Downgrade
03/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $4.5 Maintain

Investors sentiment increased to 1.25 in Q4 2017. Its up 0.58, from 0.67 in 2017Q3. It is positive, as 3 investors sold CorMedix, Inc. shares while 5 reduced holdings. 3 funds opened positions while 7 raised stakes. 3.71 million shares or 11.19% less from 4.18 million shares in 2017Q3 were reported. Vanguard Grp Inc, a Pennsylvania-based fund reported 1.70M shares. Northern holds 0% or 63,401 shares in its portfolio. Bridgeway Cap Inc has invested 0% in CorMedix, Inc. (NYSEAMERICAN:CRMD). Natl Bank Of America Corp De accumulated 32,000 shares or 0% of the stock. Private Advisor Grp Incorporated Lc owns 13,740 shares. Bnp Paribas Arbitrage Sa has 0% invested in CorMedix, Inc. (NYSEAMERICAN:CRMD). Retail Bank Of Mellon has invested 0% in CorMedix, Inc. (NYSEAMERICAN:CRMD). Geode Capital Mgmt Ltd accumulated 0% or 295,008 shares. Royal Bankshares Of Canada owns 28 shares or 0% of their US portfolio. Susquehanna Intl Grp Ltd Liability Partnership reported 41,379 shares. Brandes Invest Partners Ltd Partnership has 85,000 shares for 0% of their portfolio. Deutsche Savings Bank Ag invested in 51,600 shares. Franklin Resources invested in 180,749 shares or 0% of the stock. Blackrock reported 0% stake. Tci Wealth Advsr Inc holds 0% in CorMedix, Inc. (NYSEAMERICAN:CRMD) or 2,900 shares.

CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and other markets. The company has market cap of $19.08 million. The Company’s primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. It currently has negative earnings. The firm was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007.

Alliqua BioMedical, Inc., a regenerative technologies company, commercializes regenerative medical products that assist the body in the repair or replacement of soft tissue. The company has market cap of $11.96 million. It markets MIST Ultrasound Healing Therapy, a painless, noncontact, low-frequency ultrasound to promote healing; Biovance Amniotic Membrane Allograft and Interfyl Human Connective Tissue Matrix that are human biologic regenerative technologies; and TheraBond 3D Antimicrobial Barrier Systems that promotes an optimal wound healing by creating an antimicrobial barrier that helps protect against infection. It currently has negative earnings. The firm also provides contract manufacturing services, including the development, manufacture, and market of high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics.

Another recent and important Alliqua BioMedical, Inc. (NASDAQ:ALQA) news was published by Globenewswire.com which published an article titled: “Alliqua BioMedical, Inc. Announces Closing Asset Sale to Celularity Inc.” on May 07, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: